Mazor medical imaging system succeeds in comparative trial

The study showed that its product had similar results to other systems which are significantly more expensive.

The evidence-based medicine trend is gaining popularity among Israeli medical device companies as well. Tel Aviv Stock Exchange (TASE)-listed Mazor Surgical Technologies is joining the trend and released today the results of a comparative trial between it and systems with which it seeks to compete.

Evidence-based medicine is based on the concept that in order to market a healthcare product in the current economically-pressured world, a company, even after receiving regulatory approval, must invest in studies that show not only the product's effectiveness, but also its contribution to the patient's health in comparison with alternatives, both health-wise and economically.

Mazor's trial compared its system for three-dimensional imaging in surgery (C-Insight) to existing systems, which are ten times more expensive than Mazor's. According to Mazor, the study showed that its product had similar results to the other systems.

Mazor's share rose 15% today.

The study also showed that it was possible to reduce x-ray exposure, compared with competing systems.

The research was conducted at Hadassah Hospital. C-Insight is based on sophisticated analysis of images from x-rays, which are already located in operating rooms, in lieu of CT machines.

In the past several months, Mazor signed several agreements to set up trial systems of its C-Insight at three US hospitals and 2 hospitals in Germany.

Published by Globes [online], Israel business news - - on June 22, 2009

© Copyright of Globes Publisher Itonut (1983) Ltd. 2009

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018